Danazol in hemophilia.
letter
OA: closed
CC0
⤵ 6 in-corpus citations
Limited metadata. Only one source feed has indexed
this record so far — no abstract, full text, or open-access copy is
available through Endo Lab. The
publisher
is the canonical location for the actual content. If you have institutional
access, use "Find at my library".
AI-generated summary
This paper examines the use of danazol as a treatment option for hemophilia.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
My notes (saved in your browser only)
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (8)
- W2016782194 via openalex
- W2073966110 via openalex
- W2089160165 via openalex
- W2133639366 via openalex
- W2229112528 via openalex
- W2323757417 via openalex
- W2325263022 via openalex
- W2345856989 via openalex
Cited by (6)
- Danazol therapy in factor X deficiency 2001
- Danazol Increases the Anticoagulant Effect of Warfarin 1992
- Fibrinolysis induced by danazol 1986
- Effect of danazol on clotting factor levels, bleeding incidence, factor infusion requirements, and immune parameters in hemophilia 1986
- Danazol in Hemophilia-Reply 1985
- Danazol in Hemophilia 1985
Source provenance
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0
· commercial use OK